Patent: 7,271,143
✉ Email this page to a colleague
Summary for Patent: 7,271,143
| Title: | Peptides for regulation of urokinase (uPA) and tissue type (tPA) plasminogen activator and method of optimizing therapeutic efficacy |
| Abstract: | Compositions of the polypeptide SEQ ID NO:1, SEQ ID NO:2, anti-LRP antibodies, LRP antagonists, and/or one or more fibrinolytic agents are formulated for enhancing the fibrinolytic activity, reducing the side effects due to vasoactivity caused by the fibrinolytic agents, and/or prolonging the half lives of the fibrinolytic agents. The invention further relates to combination compositions and/or therapy regimens, comprising the polypeptide SEQ ID NO:1 and/or SEQ ID NO:2 and one or more currently used plasminogen activators. |
| Inventor(s): | Higazi; Abd. Al-Roof (Shimshon, IL) |
| Assignee: | Thrombotech Ltd. (Nazareth Illit, IL) |
| Application Number: | 10/386,777 |
| Patent Claims: | see list of patent claims |
Details for Patent 7,271,143
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Genentech, Inc. | ACTIVASE | alteplase | For Injection | 103172 | 11/13/1987 | ⤷ Try a Trial | 2021-07-10 |
| Genentech, Inc. | CATHFLO ACTIVASE | alteplase | For Injection | 103172 | 09/04/2001 | ⤷ Try a Trial | 2021-07-10 |
| Chiesi Usa, Inc. | RETAVASE | reteplase | For Injection | 103786 | 10/30/1996 | ⤷ Try a Trial | 2021-07-10 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
